Pharmacological targeting of signaling pathways

Intro to Signal Targeting - Drugging the Cell's Mail

• Core Principle: Drugs modulate cellular responses by interacting with signaling pathways, acting as agonists or antagonists.
• Key Drug Targets:
  • Receptors: GPCRs, Tyrosine Kinases, Ion Channels.
  • Second Messengers: cAMP, cGMP, IP₃, DAG, Ca²⁺.
  • Downstream Enzymes: Kinases & phosphatases.

⭐ G-protein coupled receptors (GPCRs) are the most common drug targets. Drugs can affect the receptor, G-protein, or the effector enzyme (e.g., adenylyl cyclase).

GPCR & G-Protein Targets - The G-Protein Saga

GPCRs are 7-transmembrane receptors, a major drug target. Ligand binding activates G-proteins by exchanging GDP for GTP on the α-subunit, which then modulates effector enzymes.

• Gs (stimulatory): Activates adenylyl cyclase → ↑ cAMP → PKA activation.
  • Examples: β-adrenergic agonists (albuterol), glucagon.
• Gi (inhibitory): Inhibits adenylyl cyclase → ↓ cAMP → PKA inhibition.
  • Examples: Opioids, α₂-adrenergic agonists (clonidine).
• Gq: Activates phospholipase C → ↑ IP₃ & DAG.
  • IP₃ mobilizes intracellular Ca²⁺.
  • DAG activates Protein Kinase C (PKC).
  • Examples: α₁-adrenergic agonists (phenylephrine).

⭐ Exam Favorite: Cholera toxin constitutively activates Gs by ADP-ribosylation, causing massive ↑ cAMP. Pertussis toxin inactivates Gi, also leading to ↑ cAMP.

Enzyme-Linked Receptor Drugs - Kinases on the Hit List

• Core Concept: Targets receptors with intrinsic enzymatic activity, primarily Receptor Tyrosine Kinases (RTKs). Ligand binding causes dimerization and autophosphorylation, activating downstream pathways (e.g., MAP kinase).
• Drug Strategies:
  • Tyrosine Kinase Inhibitors (TKIs): Small molecules ending in -tinib. They enter the cell and block the ATP-binding site of the kinase domain.
    • Imatinib: Targets BCR-ABL in CML.
    • Erlotinib: Targets EGFR in lung cancer.
  • Monoclonal Antibodies (mAbs): Large molecules ending in -mab. Bind to the extracellular receptor domain, blocking ligand binding.
    • Trastuzumab (Herceptin): Targets HER2 in breast cancer.

⭐ Imatinib revolutionized Chronic Myeloid Leukemia (CML) treatment by targeting the specific BCR-ABL fusion protein, a hallmark of the disease.

Other Pathway Targets - Channels, Steroids & More

• Ion Channel-Linked Receptors: Rapid signaling via ion flux.

  • Ligand-gated: Neurotransmitters (GABA, ACh) open channels. E.g., Benzodiazepines enhance GABA action.
  • Voltage-gated: Change in membrane potential opens channels. E.g., Verapamil blocks voltage-gated Ca²⁺ channels.

• Intracellular Receptors (Steroids, Thyroid Hormone):

  • Lipophilic hormones cross the cell membrane to bind cytosolic or nuclear receptors, which then act as transcription factors.

⭐ Intracellular receptors that bind DNA (e.g., for steroids, thyroid hormone, vitamin D) typically have highly conserved zinc-finger domains.

High‑Yield Points - ⚡ Biggest Takeaways

• G-protein coupled receptors (GPCRs) are the most common drug targets, modulated by agonists and antagonists.
• Tyrosine kinase inhibitors (-nibs) and monoclonal antibodies (-mabs) are crucial in cancer therapy.
• Lipid-soluble drugs like steroids target intracellular receptors to directly regulate gene transcription.
• Ion channels are key targets for drugs affecting excitable tissues (e.g., anesthetics, antiarrhythmics).
• Phosphodiesterase (PDE) inhibitors prevent second messenger breakdown, amplifying cAMP/cGMP signals.
• Chronic agonist exposure can cause receptor desensitization or downregulation, leading to drug tolerance.